Literature DB >> 18246411

A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.

Hugh K Arnold1, Rosalie C Sears.   

Abstract

Loss or inhibition of the serine/threonine protein phosphatase 2A (PP2A) has revealed a critical tumor suppressor function for PP2A. However, PP2A has also been shown to have important roles in cell cycle progression and survival. Therefore, PP2A is not a typical tumor suppressor. This is most likely due to the fact that PP2A represents a large number of different holoenzymes. Further understanding of PP2A function(s), and especially its tumor suppressor activity, will depend largely on our ability to determine specific targets for these different PP2A holoenzymes and to gain an understanding of how these targets confer tumor suppressor activity or contribute to cell cycle progression and cell survival. Recent work has identified c-Myc as a target of the PP2A holoenzyme, PP2A-B56alpha. This holoenzyme also negatively regulates beta-catenin expression and modulates the anti-apoptotic activity of Bcl2, thus characterizing PP2A-B56alpha as a tumor suppressor PP2A holoenzyme. This review will focus on the role of PP2A-B56alpha in regulating c-Myc and will place this tumor suppressor activity of PP2A within the context of its other tumor suppressor functions. Finally, the mechanism(s) through which PP2A-B56alpha tumor suppressor activity may be lost in cancer will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246411      PMCID: PMC3045695          DOI: 10.1007/s10555-008-9128-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  109 in total

Review 1.  New light on Myc and Myb. Part I. Myc.

Authors:  B Lüscher; R N Eisenman
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

2.  Mitotic arrest and enhanced nuclear protein phosphorylation in human leukemia K562 cells by okadaic acid, a potent protein phosphatase inhibitor and tumor promoter.

Authors:  B Zheng; C F Woo; J F Kuo
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

Review 3.  The myc oncogene: its role in transformation and differentiation.

Authors:  M D Cole
Journal:  Annu Rev Genet       Date:  1986       Impact factor: 16.830

4.  Rapid cytoplasmic turnover of c-myc mRNA: requirement of the 3' untranslated sequences.

Authors:  T R Jones; M D Cole
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

5.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

Authors:  A Strasser; A W Harris; M L Bath; S Cory
Journal:  Nature       Date:  1990-11-22       Impact factor: 49.962

6.  Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A.

Authors:  D C Pallas; L K Shahrik; B L Martin; S Jaspers; T B Miller; D L Brautigan; T M Roberts
Journal:  Cell       Date:  1990-01-12       Impact factor: 41.582

7.  Role of protein phosphatases in malignant transformation.

Authors:  M Nagao; R Sakai; Y Kitagawa; I Ikeda; K Sasaki; H Shima; T Sugimura
Journal:  Princess Takamatsu Symp       Date:  1989

8.  Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation.

Authors:  J Chen; B L Martin; D L Brautigan
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

9.  Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment.

Authors:  J A Coppola; M D Cole
Journal:  Nature       Date:  1986 Apr 24-30       Impact factor: 49.962

10.  Promotion of BALB/3T3 cell transformation by the okadaic acid class of tumor promoters, okadaic acid and dinophysistoxin-1.

Authors:  A Sakai; H Fujiki
Journal:  Jpn J Cancer Res       Date:  1991-05
View more
  44 in total

1.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

2.  Identification of PP2A complexes and pathways involved in cell transformation.

Authors:  Anna A Sablina; Melissa Hector; Nathalie Colpaert; William C Hahn
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

3.  Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.

Authors:  Tyler Risom; Xiaoyan Wang; Juan Liang; Xiaoli Zhang; Carl Pelz; Lydia G Campbell; Jenny Eng; Koei Chin; Caroline Farrington; Goutham Narla; Ellen M Langer; Xiao-Xin Sun; Yulong Su; Colin J Daniel; Mu-Shui Dai; Christiane V Löhr; Rosalie C Sears
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

4.  Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.

Authors:  Archana Mukhopadhyay; Kayann Tabanor; Rathnam Chaguturu; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

5.  Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels.

Authors:  Simone Buraschi; Nutan Pal; Nadia Tyler-Rubinstein; Rick T Owens; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

Review 6.  Regulation of transcription factor activity by interconnected post-translational modifications.

Authors:  Theresa M Filtz; Walter K Vogel; Mark Leid
Journal:  Trends Pharmacol Sci       Date:  2013-12-30       Impact factor: 14.819

7.  Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.

Authors:  Gernot Walter; Ralf Ruediger
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

8.  Interaction between salt-inducible kinase 2 and protein phosphatase 2A regulates the activity of calcium/calmodulin-dependent protein kinase I and protein phosphatase methylesterase-1.

Authors:  Chia-Wei Lee; Fu-Chia Yang; Hsin-Yun Chang; Hanyi Chou; Bertrand Chin-Ming Tan; Sheng-Chung Lee
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

Review 9.  The role of aurora A and polo-like kinases in high-risk lymphomas.

Authors:  Carlos Murga-Zamalloa; Kedar V Inamdar; Ryan A Wilcox
Journal:  Blood Adv       Date:  2019-06-11

10.  Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.

Authors:  Shanna K Nifoussi; Nora R Ratcliffe; Deborah L Ornstein; Gary Kasof; Stefan Strack; Ruth W Craig
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.